NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Swiss National Bank

Swiss National Bank lifted its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 105.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 72,000 shares of the company’s stock after buying an additional 36,900 shares during the period. Swiss National Bank owned approximately 0.08% of NewAmsterdam Pharma worth $1,850,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. FMR LLC grew its position in NewAmsterdam Pharma by 35.6% during the third quarter. FMR LLC now owns 330,412 shares of the company’s stock worth $5,485,000 after buying an additional 86,712 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in NewAmsterdam Pharma by 1,231.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock worth $3,972,000 after acquiring an additional 221,305 shares during the last quarter. JPMorgan Chase & Co. grew its stake in NewAmsterdam Pharma by 176.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company’s stock worth $371,000 after acquiring an additional 14,280 shares during the period. State Street Corp raised its holdings in NewAmsterdam Pharma by 168.7% in the 3rd quarter. State Street Corp now owns 37,915 shares of the company’s stock valued at $629,000 after acquiring an additional 23,805 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of NewAmsterdam Pharma by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock worth $1,433,000 after purchasing an additional 1,399 shares during the period. 89.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NAMS has been the subject of several research analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. UBS Group set a $41.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Needham & Company LLC lowered their target price on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. Scotiabank raised their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, NewAmsterdam Pharma presently has a consensus rating of “Buy” and a consensus price target of $43.33.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock opened at $21.76 on Friday. The company has a market capitalization of $2.39 billion, a price-to-earnings ratio of -8.37 and a beta of -0.04. The company’s fifty day moving average price is $21.66 and its two-hundred day moving average price is $21.20. NewAmsterdam Pharma has a one year low of $15.19 and a one year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million. As a group, sell-side analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Insider Activity

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 29,846 shares of the business’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $25.54, for a total value of $762,266.84. Following the completion of the transaction, the insider now directly owns 10,656,172 shares of the company’s stock, valued at approximately $272,158,632.88. The trade was a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now owns 15,000 shares of the company’s stock, valued at approximately $305,550. The trade was a 90.91 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 19.50% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.